Drug Product Science and Technology, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, NJ 08901, USA.
Drug Product Science and Technology, Bristol-Myers Squibb, Reeds Lane, Moreton, Wirral CH46 1QW, UK.
Int J Pharm. 2018 Apr 25;541(1-2):253-260. doi: 10.1016/j.ijpharm.2018.02.021. Epub 2018 Feb 24.
Form changes during drug product processing can be a risk to the final product quality in terms of chemical stability and bioavailability. In this study, online Raman spectroscopy was used to monitor the form changes in real time during high shear wet granulation of Compound A, a highly soluble drug present at a high drug load in an extended release formulation. The effect of water content, temperature, wet massing time and drying technique on the degree of drug transformation were examined. A designed set of calibration standards were employed to develop quantitative partial least square regression models to predict the concentration of each drug form during both wet granulation and the drying process. Throughout all our experiments we observed complex changes of the drug form during granulation, manifest as conversions between the initial non-solvated form of Compound A, the hemi-hydrate form and the "apparent" amorphous form (dissolved drug). The online Raman data demonstrate that the non-solvated form converts to an "apparent" amorphous form (dissolved drug) due to drug dissolution with no appearance of the hemi-hydrate form during water addition stage. The extent of conversion of the non-solvated form was governed by the amount of water added and the rate of conversion was accelerated at higher temperatures. Interestingly, in the wet massing zone, the formation of the hemi-hydrate form was observed at a rate equivalent to the rate of depletion of the non-solvated form with no change in the level of the "apparent amorphous" form generated. The level of hemi-hydrate increased with an increase in wet massing time. The drying process had a significant effect on the proportion of each form. During tray drying, changes in drug form continued for hours. In contrast fluid bed drying appeared to lock the final proportions of drug form product attained during granulation, with comparatively small changes observed during drying. In conclusion, it was possible to simultaneously monitor the three forms in real time during wet granulation and drying using online Raman spectroscopy. The results regarding the effect of process parameters on the degree of transformation are critical for designing a robust process that ensures a consistent form in the final drug product.
在药物产品加工过程中,形态变化可能会对最终产品的质量造成风险,包括化学稳定性和生物利用度。在这项研究中,在线拉曼光谱用于实时监测高剪切湿法制粒过程中化合物 A 形态变化,化合物 A 是一种高水溶性药物,以高载药量存在于缓释制剂中。考察了水含量、温度、湿混时间和干燥技术对药物转化程度的影响。采用一组设计的校准标准来建立定量偏最小二乘回归模型,以预测在湿法制粒和干燥过程中每种药物形态的浓度。在所有实验中,我们观察到药物形态在制粒过程中发生了复杂的变化,表现为化合物 A 的初始非溶剂化形式、半水合物形式和“表观”无定形形式(溶解药物)之间的转化。在线拉曼数据表明,非溶剂化形式由于药物溶解而转化为“表观”无定形形式(溶解药物),而在加水阶段没有出现半水合物形式。非溶剂化形式的转化程度取决于加入的水量,转化率在较高温度下加速。有趣的是,在湿混区,以与非溶剂化形式耗尽速率相当的速率形成了半水合物形式,而生成的“表观无定形”形式的水平没有变化。半水合物的水平随着湿混时间的增加而增加。干燥过程对每种形态的比例有显著影响。在托盘干燥过程中,药物形态的变化持续数小时。相比之下,流化床干燥似乎锁定了在制粒过程中获得的最终药物形态产品的最终比例,在干燥过程中观察到的变化相对较小。总之,使用在线拉曼光谱可以在湿法制粒和干燥过程中实时同时监测三种形态。关于工艺参数对转化程度影响的结果对于设计确保最终药物产品中形态一致的稳健工艺至关重要。